A new drug called olaparib, has been claimed to be effective in treating women with genetic breast cancer.

The researchers examined as many as 54 women with advanced genetic breast cancer and observed that olaparib is capable of reducing the enlargement tumors, minimizing them by nearly 40%.

It was found that the drug removed the entire growth of the cancer tumor in one of the women.

A majority of cases of breast cancer are resultant of deficiency in the BRCA-1 and BRCA-2 genes, which pose an increased risk of developing breast or ovarian cancer tumors in women.

This leads most of the women to get their breasts removed for prevention, as they suffer nearly 80% risk of developing breast cancer during the lifetime.

Olaparib, manufactured by AstraZeneca, has been recognized as the first drug belonging to the new class of drugs, created particularly for the cure of BRCA-related cancers.

Andrew Tutt, Director of the Breakthrough Breast Cancer Research Unit at King"s College London, who was the lead researcher in the team, said that the drug will yield positive outcomes.

"We are hopeful that olaparib could provide a targeted treatment for women with BRCA-related breast cancer”, he said.